Jazz (JAZZ) Director Bruce C. Cozadd Sells 7,219 Shares

What Happened

• Bruce C. Cozadd, a director of Jazz Pharmaceuticals (JAZZ), disposed of a total of 7,219 shares in transactions tied to RSU tax withholding and an open‑market sale. The filings show:
  • 2026-08-31: 10 shares sold at $244.06 each for $2,441 (tax withholding).
  • 2026-08-31: 1,209 shares sold at $241.39 each for $291,840 (tax withholding).
  • 2026-09-01: 6,000 shares sold at $250.13 each for $1,500,780 (open-market sale).
• Total proceeds across these transactions were about $1.80 million. These were sales/dispositions (not purchases).

Key Details

• Dates & prices: 8/31/2026 (10 @ $244.06; 1,209 @ $241.39), 9/1/2026 (6,000 @ $250.13).
• Shares owned after the transactions: not specified in the provided filing details.
• Footnotes of note:
  • F1: The 8/31 dispositions were sales to satisfy tax obligations from the vesting of previously granted restricted stock units (RSUs).
  • F2: The filing includes a corrected prior non‑open‑market disposition (Nov 3, 2025) of 3,193 shares for FICA tax withholding that was previously omitted.
  • F3: The 9/1 open‑market sale of 6,000 shares was made pursuant to a 10b5‑1 trading plan adopted Nov 26, 2025; the transaction was automatic, not discretionary.
• Filing timeliness: the Form 4 was filed on 2026-09-02 following the reported transactions; the filing does not indicate a late (L) designation.

Context

• Tax-withholding sales related to RSU vesting are routine and typically don’t signal a change in an insider’s view of the company. The separate 6,000-share sale was executed under a pre-arranged 10b5‑1 plan, meaning it occurred automatically according to the plan’s terms rather than as a discretionary trade by the director.